PL3562822T3 - Inhibitory polimerazy poli(adp-rybozy) (parp) - Google Patents
Inhibitory polimerazy poli(adp-rybozy) (parp)Info
- Publication number
- PL3562822T3 PL3562822T3 PL17832694T PL17832694T PL3562822T3 PL 3562822 T3 PL3562822 T3 PL 3562822T3 PL 17832694 T PL17832694 T PL 17832694T PL 17832694 T PL17832694 T PL 17832694T PL 3562822 T3 PL3562822 T3 PL 3562822T3
- Authority
- PL
- Poland
- Prior art keywords
- parp
- inhibitors
- poly
- ribose polymerase
- adp ribose
- Prior art date
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
| EP17832694.8A EP3562822B1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3562822T3 true PL3562822T3 (pl) | 2021-09-13 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17832694T PL3562822T3 (pl) | 2016-12-30 | 2017-12-28 | Inhibitory polimerazy poli(adp-rybozy) (parp) |
Country Status (33)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
| JP7512380B2 (ja) * | 2019-10-30 | 2024-07-08 | ディグムバイオ．インコーポレイテッド | イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物 |
| WO2022222921A1 (zh) * | 2021-04-22 | 2022-10-27 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
| KR20240057402A (ko) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 그람 음성 박테리아 유출 펌프 억제제 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| KR20250065924A (ko) | 2022-09-19 | 2025-05-13 | 바스프 에스이 | 아졸 살충 화합물 |
| EP4617262A1 (en) | 2022-11-07 | 2025-09-17 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2024240108A1 (zh) * | 2023-05-19 | 2024-11-28 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN117024357B (zh) * | 2023-07-03 | 2026-02-24 | 山东第二医科大学 | 一种针对brca突变的选择性抑制剂及其用途 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202608867A (zh) * | 2024-04-26 | 2026-03-01 | 美商雷密克斯醫療公司 | 用於降解週期蛋白k及抑制週期蛋白依賴性激酶之化合物及相關方法 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026030819A1 (en) * | 2024-08-08 | 2026-02-12 | Waverley Pharma Inc. | Substituted (3-hydroquinazolin-4-one) derivatives and pharmaceutical compositions thereof use as potent & selective poly [adp ribose] polymerase 1(p arp-1) inhibitors for the treatment of cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249262A1 (en) | 2000-03-20 | 2001-10-03 | Sepracor, Inc. | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| EP1272187B1 (de) | 2000-03-27 | 2008-07-30 | Abbott GmbH & Co. KG | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CA2568835C (en) * | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| CN101263125A (zh) | 2005-07-15 | 2008-09-10 | 先灵公司 | 用于癌症治疗的喹唑啉衍生物 |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2012140642A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| SG11201600743WA (en) | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| RU2016147727A (ru) | 2014-05-07 | 2018-06-08 | Мерк Патент Гмбх | Гетероциклилбутанамидные производные |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
-
2017
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 MX MX2019007870A patent/MX393606B/es unknown
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active Active
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 SM SM20210321T patent/SMT202100321T1/it unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en not_active Ceased
- 2017-12-28 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 MY MYPI2019003419A patent/MY199045A/en unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es active IP Right Grant
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003310B (en) | Poly-adp ribose polymerase (parp) inhibitors | |
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| IL268955B (en) | Selective hdac6 inhibitors | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| EP3347008A4 (en) | BETA-Lactamase INHIBITORS | |
| ZA201704293B (en) | Selective bace1 inhibitors | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| EP3244735A4 (en) | Improved pathogen inhibitor | |
| GB2544132B (en) | Inhibitors that enhance insecticide performance | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| GB201509078D0 (en) | Media routing | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201612860D0 (en) | Inhibitors | |
| EP3454852A4 (en) | PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS | |
| GB201501004D0 (en) | Inhibitors | |
| IL253322A0 (en) | bace1 inhibitors | |
| EP3525786A4 (en) | KDM5 INHIBITORS | |
| IL247025A0 (en) | enzyme inhibitors | |
| GB201520949D0 (en) | Inhibitors | |
| EP3525785A4 (en) | KDM5 INHIBITORS | |
| GB201614783D0 (en) | Kinases inhibitors |